|Bid||4,773.50 x 6100|
|Ask||4,774.00 x 13000|
|Day's Range||4,742.50 - 4,787.00|
|52 Week Range||3,996.00 - 5,520.00|
|PE Ratio (TTM)||15.66|
|Dividend & Yield||2.79 (4.51%)|
|1y Target Est||N/A|
There were multiple presentations at European Society for Medical Oncology 2017 Congress. AstraZeneca's lung cancer study data was positive and so was Bristol-Myers's melanoma candidate.
French biotech company Neovacs is confident that its experimental drug to treat lupus could grab significant market share from standard treatments of the auto-immune disease, its chief executive said. About 5 million people globally suffer from some form of lupus, the Lupus foundation of America says, affecting multiple organs and leading to a range of symptoms that can include skin rashes, swollen joints and fevers. Until now, treatments from the likes of GlaxoSmithKline (GSK) and AstraZeneca's MedImmune have focused on the use of monoclonal antibodies, but Neovacs is working on therapeutic vaccines covered by five patent families it calls kinoids, with patent protection until 2032.
AstraZeneca (AZN) recently sold its remaining rights to its anaesthetics medicines to Aspen Group for an upfront consideration of $555 million.